Canaccord raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$13 from C$12.50 and keeps a Hold rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPHRF:
- Cipher Pharmaceuticals Reports Strong Revenue Growth in Q1 2025
- Cipher Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Cipher Pharmaceuticals Reports Strong Q1 2025 Results and Strategic Debt Repayment
- CPHRF Upcoming Earnings Report: What to Expect?
- Cipher Pharmaceuticals to Announce Q1 2025 Financial Results